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Introduction
Within pathology laboratories, quality assessment, internal 
quality control (QC) and external quality assurance (EQA) are 
integral components of a laboratory’s quality system. They 
are tools to ensure that the quality of results being produced 
by laboratory testing will not compromise the clinical care 
of the patient. This criterion applies equally when the testing 
environment changes from the laboratory to the point of care, 
and the large laboratory instrument becomes a smaller device.
While the principles of quality assessment should be the same 
in the point-of-care testing (PoCT) environment, the methods 
by which they are applied will be different, depending on 
factors such as frequency of testing, complexity of the 
device, inbuilt checks manufactured into the device, cost and 
practicality of providing the quality management system, 
and the fact that non-laboratory-trained operators will most 
likely be performing the tests. As the use of PoCT increases, 
it is laboratory-trained professionals who understand the 
principles of quality assessment that are best positioned to set 
guidelines for PoCT application.
The Role of Professional Organisations
Professional organisations such as the Australasian 
Association of Clinical Biochemists (AACB), through the 
laboratory expertise of its members, have a role to play in 
providing guidance on the use of PoCT conducted outside the 
laboratory environment. The AACB believes that PoCT can 
make significant and positive clinical, economic and social 
contributions to society if used appropriately. However, all 
PoCT should be accessed and conducted within formal quality 
frameworks to ensure such testing is conducted to professional 
standards that assure fitness for medical purpose. The AACB 
PoCT Working Party has previously developed documents on 
the principles of conduct of PoCT,1 and at the time of writing 
is completing minimum guidelines specifically targeted at 
non-laboratory-trained operators for the use of QC and EQA 
in the PoCT environment. This article provides a descriptive 
supporting commentary on selected issues featured in these 
guidelines.
Scope 
Globally, the scope and application of PoCT has grown 
exponentially in the past decade principally due to significant 
technological improvements in the design and manufacture 
of PoCT device and reagent systems as well as advances in 
connectivity standards.2 
The clinical settings in which PoCT is conducted are numerous, 
including hospitals (emergency departments, wards, clinics, 
operating theatres), doctors’ surgeries, indigenous medical 
services, pharmacies, sports medicine clinics, workplaces, 
veterinary clinics and, with patient self-monitoring, the home. 
Within Australia, PoCT has come of age in the community 
setting with the successful implementation of large scale 
national PoCT programs such as the Quality Assurance 
for Aboriginal and Torres Strait Islander Medical Services 
(QAAMS) Program and the PoCT in General Practice 
Trial, together with state-wide models including Pathology 
Queensland’s i-STAT program and the iCCnet SA PoCT 
model for cardiac care.3-12
The element common to most of the aforementioned clinical 
settings is that a non-laboratory-trained person is performing 
PoCT. However, except in the case of patient self-monitoring, 
this person is usually a healthcare professional. The QC and 
EQA guidelines that have been developed by the AACB 
PoCT Working Party focus on the use of PoCT by healthcare 
professionals rather than on patient self-monitoring.
The Need for Quality Frameworks
In the laboratory setting, analytical quality is usually assessed 
by QC and EQA. The aim of conducting QC and EQA testing 
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is to monitor the stability of the analytical measurement system 
and to alert the operator to a change in stability (notably a shift 
or trend in performance, or poorer reproducibility of testing) 
that may lead to a medically important error.
While these traditional quality processes serve the laboratory 
well, a key issue which is the subject of considerable debate 
among the medical scientist fraternity worldwide is: are these 
processes relevant, transferable, practical and cost effective 
for monitoring analytical quality on PoCT devices?13,14
There is no simple answer or solution to this question. In 
attempting to address the issue, it is necessary to:
(i) have an understanding of the difference between 
laboratory and PoCT testing systems
(ii) assess the degree of technological sophistication that 
individual PoCT systems have, particularly their 
‘inbuilt’ or ‘onboard’ quality checks and level of 
connectivity 
(iii) find the appropriate balance between ensuring safety 
and analytical quality of PoCT, and implement a 
quality framework that is practicable in the field and 
cost effective.
Differences Between Laboratory and PoCT Systems
Most laboratory instruments are closed (or self-contained), 
multi-use systems that have the ability to measure large 
numbers of samples in batches throughout the day. For these 
types of analysers, the testing of multi-level QC throughout 
the day combined with monthly EQA testing and regular 
maintenance is considered standard practice.
In contrast, most PoCT devices utilise a disposable single-
use testing unit. The sample is inserted into the testing unit 
and the analyte to be measured is recognised most commonly 
through the use of chemical or biological sensors (that is, a 
reaction takes place). The second component of the PoCT 
system is the device, which in simple terms is just a reader of 
the signal generated as a result of the reaction.15,16 
There are many different types of single-use testing units 
including the cartridges used with the Abbott iSTAT, Siemens 
DCA and Axis Shield Afinion devices, the cassettes used with 
the Inverness Cholestech LDX, and the test strip-based systems 
that use a code chip for calibration, including the Roche 
CoaguChek XS, Roche Cobas h232 and Nova Biomedical 
NovaStat devices. Other examples of single-use testing units 
include the cuvette with the HemoCue haemoglobin device 
and the rotor or disc with the Abaxis Piccolo device. 
Traditional batch-based QC and EQA practices are not 
necessarily applicable to these systems as each testing unit 
is discrete and disposable, and checking the performance of 
a single testing unit does not guarantee with any certainty 
the quality of the next unit (unlike multi-use laboratory 
instruments).
QC Checks for PoCT Systems
How then have manufacturers of such systems approached the 
problem of quality management? With most modern PoCT 
devices, there has been significant technological investment 
by manufacturers in the development of sophisticated inbuilt 
quality checks within the testing unit itself. (These checks 
have been described variously as onboard QC, intelligent 
QC and internal checks.) Manufacturers have recognised 
that in the future the main consumers of PoCT will be 
health professionals from a non-laboratory background, and 
they have deliberately tried to make the devices as simple 
as possible for the operator and, at the same time, as well-
controlled internally as possible. For example, the Abbott 
i-STAT cartridge has a calibration solution contained in a 
pouch in every cartridge and performs a calibration before 
each sample is tested. Inbuilt checks of the calibration fluid 
include its freedom from bubbles, its integrity during handling 
and its correct concentration. With the Roche CoaguChek XS, 
every test strip has inbuilt control checks for strip deterioration 
due to exposure to excessive temperature and humidity (with 
the reduction of resazurin to resorufin, a highly fluorescent 
dye, correlating with the degree of strip damage). The Piccolo 
rotor quantifies interference and verifies chemistry, optics and 
electronics with every run.
In terms of the device component of the PoCT system, 
most PoCT devices feature processes by which the quality/
reliability of signal generation is monitored (known as the 
electronic QC check).17 For example, the Abbott i-STAT has 
an electronic simulator which specifically measures electrical 
signal generation and ensures that these signals are within 
tight specification limits.
It should also be noted that state-of-the-art PoCT devices 
now have advanced levels of connectivity and the ability 
to electronically capture and transmit results to a central 
management point (a central data station and/or a clinical or 
laboratory information system), ensuring that post-analytical 
errors are minimised.
Clearly, the best unit-use PoCT systems are those with the 
highest degree of built-in QC checks to monitor the analytical 
steps and the most advanced level of connectivity.
Finding the Balance
With this level of technological sophistication in PoCT 
devices today, the role of traditional QC and EQA has come 
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under question. A training manual for a widely-used PoCT 
device currently contains the following statement: ‘Quality 
control and system checks using control test solutions that 
you may be familiar with from other systems are no longer 
required …’ Certainly this is not the view of the authors, nor 
most likely the vast majority of laboratory professionals. 
For us, unquestionably, there remains a continuing place 
for traditional QC and EQA as an independent check of the 
quality of PoCT systems, but one needs to match the degree 
of technical sophistication of the device with a QC/EQA 
frequency regimen that is cost effective and practicable. 
There is no ‘one size fits all’ policy that can be applied 
universally across all PoCT testing systems, and it is for this 
reason that the AACB PoCT guidelines focus on minimum 
requirements for conducting QC and EQA testing. Certainly, 
it is a given that QC on a PoCT device should be conducted 
on a new delivery of reagents, when there is a change in 
reagent lot number, when a patient result does not fit the 
clinical presentation, and when a major maintenance or 
repair procedure has been enacted. Beyond these scenarios, 
frequency of QC testing, in particular, should take into account 
the actual volume and nature of patient testing conducted in 
the field. For example, some sites will conduct weekly clinics 
for patients with diabetes but the number of patients may vary 
widely. It is our experience that a considerable amount of 
PoCT in community settings is opportunistic, making broadly 
applicable frequencies for QC testing difficult to set.
Cost of purchasing QC and EQA materials is a factor that is of 
particular relevance (and concern) both to small health centres 
with limited financial budgets that wish to practice PoCT and 
to large PoCT networks (possibly servicing 50 or more sites) 
where costs of conducting QC and EQA at every site could 
consume a large percentage of the consumables budget.
In terms of practicality in the field, laboratory scientists should 
never lose sight of the complexities faced by a PoCT operator 
performing QC and EQA in a non-laboratory environment. 
For example, operators in the national QAAMS Program, 
who are required to conduct two levels of QC testing in the 
first fortnight and two EQA samples in the second fortnight of 
each month, must work with a range of different sealed vials, 
liquid solutions and pipetting equipment to fulfil their quality 
testing requirements. The realities of PoCT conducted in the 
field by busy health professionals who are not familiar with 
laboratory practice are often overlooked or misunderstood by 
the laboratory-based scientist.
EQA Checks for PoCT Systems
EQA programs are a component of a continuous quality 
assessment and improvement cycle and under International 
Organization for Standardization (ISO) are a mandatory 
requirement for medical laboratories.18 The benefits of 
participation in EQA include an assessment of the accuracy 
of results against an assigned value, comparison with all 
instruments, peer comparison with the same instrument, 
assessment of performance over time, and providing confidence 
that the results reported on patients are correct. These benefits 
apply equally to PoCT. Therefore EQA is both desirable and 
required for PoCT devices. The requirement is reflected in 
the international standard, ISO 22870 Point-of-care testing 
(POCT) - requirements for quality and competence,19 and in 
The National Academy of Clinical Biochemistry Evidence-
Based Practice for Point-of-Care Testing.20 
An alternative to formal EQA testing is ‘split’ or ‘parallel’ 
patient sample testing in which the same patient sample is 
tested by PoCT and by the laboratory. Potential advantages of 
split sample testing are: (a) like EQA, it provides a delayed 
external check of quality; (b) testing utilises a sample of 
identical matrix (e.g. whole blood) to that of routine patient 
samples rather than a lyophilised EQA material; (c) it can 
be a cost-effective external assessment of quality; and (d) 
with samples equivalent to routine specimens, it can check 
the pre-analytical component of testing. However, potential 
drawbacks of split sample testing include: (a) testing only a 
limited range of concentrations vs EQA with its ability to test 
an analytical method across the range of concentrations seen 
in health and disease; (b) a lack of peer comparison; (c) the 
need to define appropriate acceptability criteria that recognise 
measurement uncertainty; and (d) problems associated with 
transport and delivery of patient samples to the laboratory 
from geographically isolated rural and remote locations.
Who Should Perform the Quality Testing?
There is still a tendency at some PoCT sites, especially in 
hospitals, to consider that laboratory staff or the PoCT co-
ordinator, for example a diabetes educator, should run the 
QC and EQA samples. The reasoning behind this can be time 
considerations or the desire to get the ‘best’ result. However if 
we go back to the ultimate purpose of these checks – to ensure 
that the quality of results will not compromise patient care – 
then it follows that the operator who is performing the testing 
should be the one performing the quality checks. Where there 
are multiple operators, all should be rotated through this 
process.
Who Should Review the Quality Testing?
QC is an immediate check on the integrity of the PoCT device 
and therefore the operator should record the result and take 
appropriate action at the time of testing. However there 
should be regular review of QC and EQA results as part of the 
cycle of quality improvement. This follow-up can be an area 
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of weakness in PoCT, but it is an opportunity for laboratory 
professionals with expertise to provide such training to PoCT 
co-ordinators or for them to consult directly.
Conclusion
This article is designed to provide readers with a brief 
discussion of some of the issues relevant to the conduct of 
PoCT outside the laboratory. The article acknowledges that 
there is no single strategy that can be universally adopted across 
all of the clinical settings in which PoCT is now conducted in 
Australasia. Rather, a tailored, flexible and balanced approach 
taking into account technological sophistication, practicality, 
cost and size/scope of PoCT networks is required. The 
discussion presented is consistent with and supportive of the 
guidelines for the conduct of QC and EQA being developed 
by the AACB PoCT Working Party. 
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